title: Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)- N-(3,3,3-[(18)F]trifluoropropyl)acetamide, [(18)F]EF3.
abstract: The 2-nitroimidazole derivative 2-(2-nitroimidazol-1-yl)- N-(3,3,3-trifluoropropyl)acetamide (EF3) is a marker which forms adducts into hypoxic cells. Radiosynthesis of [(18)F]EF3 was recently performed by our group. Our aim was to study the pharmacokinetics, biodistribution, metabolism and specificity for hypoxia of [(18)F]EF3. MCa-4, SCC VII, NFSA, FSA, FSA II or Sa-NH tumour-bearing C3H mice were injected intravenously with [(18)F]EF3 and allowed to breathe air, 10% O(2) or carbogen until sacrifice 5-770 min after injection. Radioactivity was measured ex vivo in various organs, including urine and faeces. Selected organs were additionally processed to measure tracer metabolites with high-performance liquid chromatography. The half-life in blood was 73.9 min. [(18)F]EF3 was eliminated mainly via the kidneys, with 75% of the injected activity found in the urine by 12 h 50 min. The biodistribution was fast and homogeneous except in the brain and the bone, where it was significantly lower, and in the liver and the kidney, where it was significantly higher. In most organs, the exceptions being the gastrointestinal and urinary tract, tissue-to-blood ratios were below or close to unity. In tumours, a relative accumulation of the tracer was observed with time, which, at 220 min after injection, depended on tumour strain and oxygenation conditions, i.e. 10% O(2) significantly increased the tumour-to-muscle ratio whereas carbogen decreased it. [(18)F]EF3 was rapidly metabolised in the kidney and the liver. [(18)F]EF3 is a promising tracer for detection of tumour hypoxia. A phase I study in head and neck cancer patients is in progress at our institution.
authors.affiliation: Department of Radiation Oncology and Radiobiology Unit, Université catholique de Louvain, St-Luc University Hospital, 10 Ave Hippocrate, 1200, Brussels, Belgium.
authors.forename: P
authors.initials: P
authors.lastname: Mahy
authors.forename: M
authors.initials: M
authors.lastname: De Bast
authors.forename: P H
authors.initials: PH
authors.lastname: Leveque
authors.forename: J
authors.initials: J
authors.lastname: Gillart
authors.forename: D
authors.initials: D
authors.lastname: Labar
authors.forename: J
authors.initials: J
authors.lastname: Marchand
authors.forename: V
authors.initials: V
authors.lastname: Gregoire
mesh_terms: D000818:Animals; D002277:Carcinoma / Q000000981:diagnostic imaging* / Q000378:metabolism*; D015687:Cell Hypoxia; D045744:Cell Line, Tumor; D004353:Drug Evaluation, Preclinical; D005354:Fibrosarcoma / Q000000981:diagnostic imaging* / Q000378:metabolism*; D008297:Male; D008657:Metabolic Clearance Rate; D051379:Mice; D008809:Mice, Inbred C3H; D009593:Nitroimidazoles / Q000493:pharmacokinetics*; D009928:Organ Specificity; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D014018:Tissue Distribution
chemical_list: C438056:2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide; D009593:Nitroimidazoles; D019275:Radiopharmaceuticals